To new platinum(II) complexes have been synthesized and their anti-tumour and anti-HIV activities have been evaluated.
Introduction
The 1969 paper by Rosenberg et al. on the anti-tumoral activity of platinum complexes markedly increased the interest in metal-based drugs, evidenced by the 1974 review by Cleare2.
Cis-platin (cis-diammine-dichloro-platinum(II) or CDDP) has potent anti-tumour effects not only on murine tumours such as L1210 leukemia and sarcoma 180(3), but also on various kinds of human tumours including testicular, ovarian, vaginal cervix, lung, bladder, head and neck tumours.
However, it has serious adverse effects such as nephrotoxicity, nausea and vomiting, which clearly limit the efficacy of the drug (4). Many analogues of cis-platin have since been synthesized and tested, in attempts to develop new complexes which may be less toxic and which may have a different spectrum of activity; including activity against cis-platin resistant lines. One of the first new drugs was cis-diammine-(1,1-cyclobutanedicarboxylate)platinum (II), or carboplatin. It has similar activity to cis-platin, but is less toxic. These new analogues were classed as second generation drugs: three of them are shown in Figure 1 . It has been demonstrated recently that CDDP-resistant tumours such as a subline of murine L1210 (6 7) leukemia 5 and human cell tumour lines show a high cross-resistance to CBDCA in studies carried out in vitro.
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As part of a search for effective platinum-based drugs with lesser collateral effects, differences in hydrophilicity and lipophilicity and in reactivity in biological media, with the potential of oral administration, we have initiated studies with complexes containing organo-fluoro < and mixed amine ligands ) lerfluoro-carboxylate ligands should be more labile than corresponding complexes without fluorine, just as perfluorocarboxylic acids are more acidic than the corresponding acids without fluorine. However the increase in lability may not be enough to attain that of a chloro ligand. We judge this to be the case for the tetrafluorophthalate ligands. This might lead to longer life in biological media and increase the chances of reaching some tumours. Collateral effects may also be ameliorated.
As regards the amine ligands, changes in these may also modify the intrinsic chemotherapeutic effects as well as altering physical properties and thus distribution of the drug in vivo.
With this background, we have prepared two new perfluorocarboxylate complexes containing one ammine and also one amino type ligand. They have been tested for anti-cancer and anti-HIV activity.
Results and Discussion
The present work is part of a wider study of potential third generation platinum anti-cancer drugs. The selection of the new complexes stemmed from the following considerations: (i) the complexes should be neutral molecules and with configuration cis; (ii) they should contain two different amine ligands; (iii) they should contain a perfluoro-dicarboxylate type ligand. This may give them lability between those of carboplatin and cis-platin and greater lipophilicity than either. The level of lability in biological media may enable them to reach tumours requiring considerable time for access. They may have greater ability to pass through cell membranes. (9) It has been suggested for cis-platin that after penetration of the cell membrane the chlorine atoms are displaced by aquo (or possible hydroxy) ligands; while it is the new complex which interacts more readily with the nucleophilic centres of nucleotides. Figure 2 shows the analogous situation with our complexes. Complex 1 (MMF3): 1.0 g of K2PtC14 (2.4. mmoles) and 1.6 g of KI (9.6 mmoles) were dissolved in 10 ml of water with stirring. Morpholine (0.42 g; 0.42 ml; 4.8 mmoles) was then added while cooling the reaction mixture in an ice bath. C, 8.68; H, 2.18; N, 5.06; 1, 45.85; Pt, 35.27. Found: C, 8.70; H, 2.12; N, 4.85; 1, 45.55; Pt, 34.80. Mp 160C Elemental analysis (%)calculated for cis-[Pt{C6F4(CO2)2}(C4H9NO)(NH3)], (MMF3): C, 26.93; H, 2.26; N, 5.23; F, 14.20; Pt, 36.46. Found: C, 25.90; H, 2.23, N, 4.90; F, 13.85; Pt, 35.85. Mp 194C 
